Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Share-based Compensation: 2016-2025

Historic Share-based Compensation for Summit Therapeutics (SMMT) over the last 10 years, with Sep 2025 value amounting to $130.8 million.

  • Summit Therapeutics' Share-based Compensation rose 575.03% to $130.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $631.7 million, marking a year-over-year increase of 1196.53%. This contributed to the annual value of $51.0 million for FY2024, which is 261.36% up from last year.
  • Per Summit Therapeutics' latest filing, its Share-based Compensation stood at $130.8 million for Q3 2025, which was down 72.69% from $478.8 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Share-based Compensation high stood at $478.8 million for Q2 2025, and its period low was $705,000 during Q3 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $11.0 million (2024), whereas its average is $62.3 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first slumped by 74.80% in 2023, then surged by 4,218.04% in 2025.
  • Over the past 5 years, Summit Therapeutics' Share-based Compensation (Quarterly) stood at $5.6 million in 2021, then slumped by 52.70% to $2.7 million in 2022, then surged by 229.31% to $8.8 million in 2023, then grew by 25.84% to $11.0 million in 2024, then spiked by 575.03% to $130.8 million in 2025.
  • Its last three reported values are $130.8 million in Q3 2025, $478.8 million for Q2 2025, and $11.1 million during Q1 2025.